Immix Biopharma Inc
IMMX2.540USD
-0.110-4.15%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
70.74MValor de mercado
PerdaP/L TTM
Mais detalhes de Immix Biopharma Inc Empresa
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Informações da empresa
Código da empresaIMMX
Nome da EmpresaImmix Biopharma Inc
Data de listagemDec 16, 2021
CEODr. Ilya Rachman, M.D., Ph.D.
Número de funcionários18
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 16
Endereço11400 West Olympic Blvd.
CidadeLOS ANGELES
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal90064
Telefone18889581084
Sitehttps://immixbio.com/
Código da empresaIMMX
Data de listagemDec 16, 2021
CEODr. Ilya Rachman, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vladimir Torchilin, Ph.D.
Dr. Vladimir Torchilin, Ph.D.
Scientific Co-Founder
Scientific Co-Founder
--
--
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 15 de mai
Atualizado em: qui, 15 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Hsu (Jason)
17.45%
GKCC, LLC
11.64%
Rachman (Ilya M)
4.09%
Ng (Carey)
3.75%
Bleichroeder LP
3.05%
Other
60.03%
Investidores
Investidores
Proporção
Hsu (Jason)
17.45%
GKCC, LLC
11.64%
Rachman (Ilya M)
4.09%
Ng (Carey)
3.75%
Bleichroeder LP
3.05%
Other
60.03%
Tipos de investidores
Investidores
Proporção
Individual Investor
28.71%
Corporation
11.64%
Investment Advisor/Hedge Fund
7.98%
Investment Advisor
4.27%
Research Firm
0.06%
Venture Capital
0.05%
Other
47.29%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
65
14.67M
52.67%
-1.12M
2025Q1
66
14.50M
53.34%
-1.02M
2024Q4
67
14.42M
52.43%
-1.29M
2024Q3
66
15.60M
56.77%
-243.92K
2024Q2
66
15.89M
59.32%
-308.72K
2024Q1
64
15.43M
77.52%
+5.90M
2023Q4
57
11.10M
62.12%
+3.00M
2023Q3
52
12.47M
73.23%
+2.63M
2023Q2
46
9.35M
66.71%
-203.85K
2023Q1
40
9.11M
65.58%
-364.69K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Hsu (Jason)
4.86M
17.45%
--
--
Apr 22, 2025
GKCC, LLC
3.24M
11.64%
--
--
Apr 22, 2025
Rachman (Ilya M)
1.14M
4.09%
+2.18K
+0.19%
Jun 18, 2025
Ng (Carey)
1.05M
3.75%
--
--
Apr 22, 2025
Bleichroeder LP
850.00K
3.05%
--
--
Mar 31, 2025
Cable Car Capital LLC
779.36K
2.8%
-16.74K
-2.10%
Mar 31, 2025
The Vanguard Group, Inc.
698.54K
2.51%
--
--
Mar 31, 2025
Morris (Gabriel S)
583.04K
2.09%
+2.23K
+0.38%
Jun 18, 2025
Lynwood Capital Management Inc.
405.00K
1.45%
+405.00K
--
Mar 31, 2024
Adams (Helen C)
174.75K
0.63%
-227.00
-0.13%
Apr 22, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporção0.01%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
